These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 15119820)
1. Cancer gene suppression strategies: issues and potential. Passioura T; Symonds G Curr Issues Mol Biol; 2004 Jul; 6(2):89-101. PubMed ID: 15119820 [TBL] [Abstract][Full Text] [Related]
2. Antisense regulation of oncogenes in human cancer. Mukhopadhyay T; Roth JA Crit Rev Oncog; 1996; 7(3-4):151-90. PubMed ID: 9258601 [TBL] [Abstract][Full Text] [Related]
3. Antisense oligonucleotides: the state of the art. Aboul-Fadl T Curr Med Chem; 2005; 12(19):2193-214. PubMed ID: 16178780 [TBL] [Abstract][Full Text] [Related]
5. Nucleic acid modulation of gene expression: approaches for nucleic acid therapeutics against cancer. Nakata Y; Kim TK; Shetzline S; Gewirtz AM Crit Rev Eukaryot Gene Expr; 2005; 15(2):163-82. PubMed ID: 16022634 [TBL] [Abstract][Full Text] [Related]
6. Validation of telomerase and survivin as anticancer therapeutic targets using ribozymes and small-interfering RNAs. Zaffaroni N; Pennati M; Folini M Methods Mol Biol; 2007; 361():239-63. PubMed ID: 17172716 [TBL] [Abstract][Full Text] [Related]
7. Antisense of oligonucleotides and the inhibition of oncogene expression. Prins J; de Vries EG; Mulder NH Clin Oncol (R Coll Radiol); 1993; 5(4):245-52. PubMed ID: 8398922 [TBL] [Abstract][Full Text] [Related]
8. Antisense therapy for cancer. Gleave ME; Monia BP Nat Rev Cancer; 2005 Jun; 5(6):468-79. PubMed ID: 15905854 [TBL] [Abstract][Full Text] [Related]
9. Antisense approaches to cancer gene therapy. Mercola D; Cohen JS Cancer Gene Ther; 1995 Mar; 2(1):47-59. PubMed ID: 7621254 [TBL] [Abstract][Full Text] [Related]
10. Rational design of sequence-specific oncogene inhibitors based on antisense and antigene oligonucleotides. Hélène C Eur J Cancer; 1991; 27(11):1466-71. PubMed ID: 1835863 [TBL] [Abstract][Full Text] [Related]
11. Oligonucleotides as modulators of cancer gene expression. Curcio LD; Bouffard DY; Scanlon KJ Pharmacol Ther; 1997; 74(3):317-32. PubMed ID: 9352587 [TBL] [Abstract][Full Text] [Related]
12. Trace of survivin in cancer. Shojaei F; Yazdani-Nafchi F; Banitalebi-Dehkordi M; Chehelgerdi M; Khorramian-Ghahfarokhi M Eur J Cancer Prev; 2019 Jul; 28(4):365-372. PubMed ID: 29847456 [TBL] [Abstract][Full Text] [Related]
13. In vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment. Cobaleda C; Sánchez-García I Blood; 2000 Feb; 95(3):731-7. PubMed ID: 10648380 [TBL] [Abstract][Full Text] [Related]
14. Targeting human telomerase by antisense oligonucleotides and ribozymes. Folini M; Pennati M; Zaffaroni N Curr Med Chem Anticancer Agents; 2002 Sep; 2(5):605-12. PubMed ID: 12678727 [TBL] [Abstract][Full Text] [Related]
16. Anti-oncogene and tumor suppressor gene therapy--examples from a lung cancer animal model. Zhang WW; Roth JA In Vivo; 1994; 8(5):755-69. PubMed ID: 7727723 [TBL] [Abstract][Full Text] [Related]
17. Antisense strategies for the treatment of hematological malignancies and solid tumors. Kronenwett R; Haas R Ann Hematol; 1998; 77(1-2):1-12. PubMed ID: 9760146 [TBL] [Abstract][Full Text] [Related]
18. Knocking down gene expression with dendritic vectors. Raviña M; Paolicelli P; Seijo B; Sanchez A Mini Rev Med Chem; 2010 Jan; 10(1):73-86. PubMed ID: 20380642 [TBL] [Abstract][Full Text] [Related]
19. Antisense inhibition: oligonucleotides, ribozymes, and siRNAs. Zhang YC; Taylor MM; Samson WK; Phillips MI Methods Mol Med; 2005; 106():11-34. PubMed ID: 15375310 [No Abstract] [Full Text] [Related]
20. Custom cancer therapies: safe and effective treatments for most or all cancers. Summerton JE Ann N Y Acad Sci; 2003 Dec; 1002():189-96. PubMed ID: 14751835 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]